IL6 and psoriasis: Punicalagin directly inhibited abnormal keratinocyte proliferation induced by inflammatory factors such as TNF-α, IL-17A, and IL-6 by suppressing S-phase kinase-associated protein 2 (SKP2) expression in both in vitro HaCaT cells and in vivo models, suggesting its potential as a promising treatment for psoriasis [102].